Bellicum Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe® safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch.
[Bellicum Pharmaceuticals, Inc.]
Sorry, but the selected Zotpress account can't be found.
